Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference [Yahoo! Finance]
LowReport
Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference [Yahoo! Finance]
Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its price target lowered by analysts at Wedbush from $24.00 to $13.00. They now have an "outperform" rating on the stock.
MediumReport
Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its price target lowered by analysts at Wedbush from $24.00 to $13.00. They now have an "outperform" rating on the stock.
Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its price target lowered by analysts at HC Wainwright from $17.00 to $14.00. They now have a "buy" rating on the stock.
MediumReport
Vigil Neuroscience, Inc. (NASDAQ: VIGL) had its price target lowered by analysts at HC Wainwright from $17.00 to $14.00. They now have a "buy" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: